{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:01:26Z","timestamp":1761490886530},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11899-019-00544-6","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T16:32:44Z","timestamp":1571848364000},"page":"561-569","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Driving the CAR to the Bone Marrow Transplant Program"],"prefix":"10.1007","volume":"14","author":[{"given":"Hema","family":"Dave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Jerkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jacobsohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"544_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.7150\/jca.2.331","volume":"2","author":"DL Porter","year":"2011","unstructured":"Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric antigen receptor therapy for B-cell malignancies. J Cancer. 2011;2:331\u20132.","journal-title":"J Cancer"},{"issue":"26","key":"544_CR2","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"\u2022 Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323. A comprehensive review of CD19 CAR-T clinical trials.","journal-title":"Blood."},{"issue":"16","key":"544_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"\u2022\u2022 Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. Two-year follow-up of the 30 patients treated with CTL019 CD19 CAR-T cells.","journal-title":"N Engl J Med"},{"issue":"4","key":"544_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","volume":"99","author":"ML Davila","year":"2014","unstructured":"Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol. 2014;99(4):361\u201371.","journal-title":"Int J Hematol"},{"issue":"9967","key":"544_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"L DW","year":"2015","unstructured":"\u2022\u2022 DW L, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328. Phase 1 clinical trial of 21 children and adults with CD19+ malignancies treated at the National Cancer Institute.","journal-title":"Lancet."},{"key":"544_CR6","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u201338.","DOI":"10.1172\/JCI85309"},{"issue":"25","key":"544_CR7","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"\u2022\u2022 Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u201331. Describes the impact of lymphodepleting regimens and CD19 antigen burden on sustained CAR engraftment and durable remissions.","journal-title":"Blood"},{"key":"544_CR8","doi-asserted-by":"crossref","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","DOI":"10.1038\/nm.4441"},{"key":"544_CR9","unstructured":"FDA approval brings first gene therapy to the United States. 2017."},{"key":"544_CR10","unstructured":"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. 2017."},{"key":"544_CR11","unstructured":"at USFaDAFatfawrorlB-clA. www. \nfda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm606540.htm\n\n. 2018."},{"issue":"14","key":"544_CR12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMp1711886","volume":"377","author":"L Rosenbaum","year":"2017","unstructured":"Rosenbaum L. Tragedy, perseverance, and chance - the story of CAR-T therapy. N Engl J Med. 2017;377(14):1313\u20135.","journal-title":"N Engl J Med"},{"key":"544_CR13","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31\u201342.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"544_CR14","doi-asserted-by":"crossref","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285\u201395.","DOI":"10.1016\/j.ymthe.2016.10.020"},{"issue":"6","key":"544_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","volume":"24","author":"K Perica","year":"2018","unstructured":"Perica K, Curran KJ, Brentjens RJ, Giralt SA. Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center. Biol Blood Marrow Transplant. 2018;24(6):1135\u201341.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"544_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"\u2022\u2022 Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood."},{"key":"544_CR17","doi-asserted-by":"crossref","unstructured":"\u2022 Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362. This review describes the recommendations for monitoring and treatment for CAR-T related toxicities by the CAR-T-cell-associated TOXicity working group (CARTOX) which included experts from various institutions and disciplines with expertise in delivering CAR-T therapy in adults with leukemia or lymphoma.","DOI":"10.1038\/nrclinonc.2017.148"},{"issue":"5","key":"544_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"\u2022\u2022 Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. Results of the phase 2 trial assessing the efficacy, safety, and cellular kinetics of tisagenlecleucel in 75 patients with at least 3\u00a0months of follow-up.","journal-title":"N Engl J Med"},{"issue":"1","key":"544_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"\u2022 Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. JULIET trial contributing to the approval of CAR-T cells in DLBCL.","journal-title":"N Engl J Med"},{"issue":"26","key":"544_CR20","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"\u2022 Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"544_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2019","unstructured":"\u2022\u2022 Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16(1):45\u201363. Guidelines for management of pediatric patients with CAR-T-related toxicities.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"544_CR22","first-page":"20","volume":"23","author":"L Taylor","year":"2019","unstructured":"Taylor L, Rodriguez ES, Reese A, Anderson K. Building a program: implications for infrastructure, nursing education, and training for CAR T-cell therapy. Clin J Oncol Nurs. 2019;23(2):20\u20136.","journal-title":"Clin J Oncol Nurs"},{"key":"544_CR23","doi-asserted-by":"crossref","unstructured":"Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, et al. Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019.","DOI":"10.1038\/s41409-019-0451-2"},{"issue":"5","key":"544_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","volume":"13","author":"KC Pehlivan","year":"2018","unstructured":"Pehlivan KC, Duncan BB, Lee DW. CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Curr Hematol Malig Rep. 2018;13(5):396\u2013406.","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"544_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"\u2022\u2022 Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. Most recent guidelines for grading and management of CRS and ICANS.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"544_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","volume":"26","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26(2):111\u20137.","journal-title":"Trends Immunol"},{"key":"544_CR27","doi-asserted-by":"crossref","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664\u201379.","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"544_CR28","doi-asserted-by":"crossref","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124\u2013e31.","DOI":"10.1097\/CCM.0000000000002053"},{"issue":"1","key":"544_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","volume":"2016","author":"NV Frey","year":"2016","unstructured":"Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):567\u201372.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"544_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137.","journal-title":"Oncologist."},{"issue":"5","key":"544_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MPH.0000000000001479","volume":"41","author":"A Taraseviciute","year":"2019","unstructured":"Taraseviciute A, Broglie L, Phelan R, Bhatt NS, Becktell K, Burke MJ. What is the role of hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) in the age of chimeric antigen receptor T-cell (CART) therapy? J Pediatr Hematol Oncol. 2019;41(5):337\u201344.","journal-title":"J Pediatr Hematol Oncol"},{"key":"544_CR32","unstructured":"Administration. USFaD. Approved risk evaluation and mitigation strategies (REMS). Kymriah (tisagenlecleucel). . 2018."},{"key":"544_CR33","volume-title":"Approved risk evaluation and mitigation strategies (REMS). Yescarta (axicabtagene ciloleucel)","author":"Administration. USFaD","year":"2018","unstructured":"Administration. USFaD. Approved risk evaluation and mitigation strategies (REMS). Yescarta (axicabtagene ciloleucel). 2018."},{"issue":"5","key":"544_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"\u2022\u2022 Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 car therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359. Long-term follow-up data of the CAR-T experience at Memoral Sloan Kettering Cancer Center.","journal-title":"N Engl J Med"},{"key":"544_CR35","doi-asserted-by":"crossref","unstructured":"Wang GP, Levine BL, Binder GK, Berry CC, Malani N, McGarrity G, et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther. 2009;17(5):844\u201350.","DOI":"10.1038\/mt.2009.16"},{"key":"544_CR36","volume-title":"Long term follow-up after administration of human gene therapy products","author":"Services USDoHaH","year":"2018","unstructured":"Services USDoHaH. Long term follow-up after administration of human gene therapy products. July 2018."},{"key":"544_CR37","doi-asserted-by":"crossref","unstructured":"Pasquini MP, Real World M. Data on CAR T-cell recipients: are we there yet? The hematologist. 2019;16(2).","DOI":"10.1182\/hem.V16.2.9405"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-019-00544-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T23:51:48Z","timestamp":1603324308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-019-00544-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-00544-6","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"23 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance With Ethical Standards"}},{"value":"H. D has received funding from the Lymphoma Research Foundation. L. J, none, D. J, none, P.J.H is a cofounder of Mana Therapeutics and is on the board of directors of Mana Therapeutics, C.M.B. is on the scientific advisory board (SAB) for Cellectis, has stock options in Neximmune, Torque Therapeutics, and Cabaletta Bio and is a cofounder and Scientific Advisory Board member of Mana Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}